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 Abstract 
Background: We pooled two clinical trials of tenecteplase compared with alteplase for the 
treatment of acute ischemic stroke, one demonstrating superiority of tenecteplase, while the 
other showed no difference between the treatments on patient clinical outcomes. We tested 
the hypotheses that reperfusion therapy with tenecteplase would be superior to alteplase in 
improving functional outcome in the group of patients with target mismatch as identified with 
advanced imaging. Methods: We investigated if tenecteplase treated patients had a different 
24h reduction in the National Institutes of Health Stroke Scale (NIHSS) and a favourable 
odds ratio of a modified Rankin scale (mRS) of 0-1vs 2-6 compared with alteplase treated 
patients using linear regression to generate odds ratios (OR). Imaging outcomes included 
rates of vessel recanalisation and infarct growth at 24 hours and occurrence of large 
parenchymal haematoma. Baseline CT perfusion was analysed to assess if patients met the 
target mismatch criteria (absolute mismatch volume >15mL, mismatch ratio >1.8, an baseline 
ischemic core <70mL, and volume of severely hypoperfused tissue <100mL). Patients 
meeting target mismatch criteria were analysed as a subgroup to identify if they had different 
treatment responses than the pooled group. Results: From 146 pooled patients, 71 received 
alteplase and 75 received tenecteplase. Tenecteplase treated patients had greater early clinical 
improvement (median NIHSS change, tenecteplase 7, alteplase 2, p=0.018) and less 
parenchymal haematoma (2/75 vs 10/71, p=0.02). The pooled group did not show improved 
patient outcomes when treated with tenecteplase (mRS 0-1 OR 1.77, 95% CI 0.89-3.51, 
p=0.102) compared with alteplase therapy. However, in patients with target mismatch (33 
tenecteplase, 35 alteplase), treatment with tenecteplase was associated with greater early 
clinical improvement (median NIHSS change, tenecteplase 6, alteplase 1, p<0.001) and better 
late independent recovery (mRS 0-1, OR 2.33, 95% CI 1.13-5.94, p=0.032) than those treated 
with alteplase. Conclusion: Tenecteplase may offer an improved efficacy and safety profile 
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versus alteplase, benefits possibly exaggerated in patients with baseline CT perfusion defined 
target mismatch. Clinical trial registration: NCT01472926 
(https://clinicaltrials.gov/ct2/show/NCT01472926) and ACTRN12608000466347 
(https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83125&isReview=true) 
Key words: stroke, ischemic; thrombolysis; perfusion imaging 
 
Clinical Perspective: 
 Tenecteplase for ischemic stroke may result in improved patient outcomes compared 
to current standard of care alteplase, however clinical trials showing varying results. 
 We have shown that patients with mismatch as identified on baseline computed 
tomography perfusion imaging show significantly improved clinical outcomes when 
treated with tenecteplase as compared to alteplase.  
 
Introduction - 
Tenecteplase offers a potential advance in acute thrombolysis for acute ischemic 
stroke with improved pharmacokinetic and pharmacodynamic over current standard of care 
alteplase. The Australian-TNK phase IIb trial found that patients randomised to tenecteplase 
0.25mg/kg had double the rate of recanalisation leading to double the rate of patients living 
with minimal disability at day 90 compared with patients randomised to alteplase 0.9 
mg/kg1,2. In this trial, baseline computed tomography perfusion (CTP) was used to identify a 
treatment responsive patient group with a visible penumbral pattern.3 Penumbral imaging has 
been the focus of much research and is a clinically available advanced imaging patient 
assessment used to identify salvageable cerebral tissue and demarcate this tissue from 
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infarcted brain to measure a ratio of salvageable brain to infarcted brain called mismatch. The 
refined concept of target mismatch was tested in the Diffusion and Perfusion Imaging 
Evaluation for Understanding Stroke Evolution 2 (DEFUSE 2) study4 to show that patients 
with target mismatch had an 8.8 time greater chance of a better 90 day outcome with 
reperfusion compared with patients without target mismatch. The large treatment effect is 
presumably due to the preferential treatment of patients who have a substantial volume of 
brain to salvage, which would otherwise infarct and cause substantial long term disability. 
Automation of baseline imaging processing was not available during the Australian-TNK 
study and investigators were required to visually identify penumbra on baseline perfusion 
imaging which lead to some enrolled patients not meeting the target mismatch criteria due to 
clinician judgment error. Therefore, reanalysis with automated imaging post processing may 
be of value.  
The Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis, (ATTEST) 
phase IIb trial acquired similar baseline multimodal CT imaging for use as an outcome 
biomarker. However, in order to explore a less selected but more generaliseable patient 
population, ATTEST did not require target mismatch for an inclusion criteria and did not 
replicate the Australian-TNK results.5 We sought to pool clinical and perfusion imaging from 
two studies to compare the treatment effect of tenecteplase vs alteplase on clinical and 
imaging biomarkers of outcomes. We hypothesised that patients classified as having target 
mismatch would be more likely to have a superior treatment effect of tenecteplase over 
alteplase on clinical outcomes. 
Methods  
Trials description 
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The Australia-TNK and ATTEST trials were Prospective, Randomised, Open, 
Blinded End-point (PROBE) studies comparing the efficacy and safety of alteplase and 
tenecteplase in thrombolysis-eligible patients with acute ischaemic stroke, using clinical and 
imaging biomarkers for outcome evaluation. The Australia-TNK study recruited from three 
sites and ATTEST was a single centre study. For both studies, patients were eligible if they 
had a clinically diagnosed supratentorial acute ischaemic stroke with a measurable deficit on 
the NIH stroke scale (NIHSS, range 0-42, 0 indicating no symptoms and 42 death), were aged 
≥18 years, were living independently pre-stroke, and were considered eligible for intravenous 
thrombolysis according to clinical guidelines. Both studies included patients over 80 years of 
age. Both trials excluded patients with major early ischemic change on non-contrast CT 
(NCCT) defined as 1) hyperdense MCA/basilar artery sign; 2) sulcal effacement; (3) basal 
ganglia/subcortical hypodensity; and (4) loss of cortical grey-white matter differentiation. In 
ATTEST patients had to be presenting to hospital within 4.5 hours of symptom onset, and in 
the Australian study patients were included up to 6 hours post-onset. In ATTEST patients 
were randomised to either tenecteplase 0.25mg/kg or alteplase 0.9mg/kg treatment on a 1:1 
basis. The Australia-TNK trial randomised patients to alteplase 0.9mg/kg or one of two doses 
of tenecteplase (0.1 mg/kg or 0.25 mg/kg) on a 1:1:1 basis. This analysis pooled trial data on 
patients receiving the 0.25 mg/kg tenecteplase dose or 0.9 mg/kg alteplase, and excluded the 
0.1mg/kg group from analysis due to the lack of a dose comparator. A key inclusion criteria 
difference between the two trials was that for Australia-TNK patients were required to have 
visible CTP mismatch (by qualitative assessment), and an intracranial vessel occlusion on 
CTA (excluding internal carotid artery  occlusions) before randomisation. ATTEST used 
standard of care NCCT thrombolysis eligibility, obtaining advanced CT imaging (CTP and 
CTA) following randomisation, but prior to therapy initiation. Initial stroke severity 
evaluated by NIHSS score was measured in all patients acutely and at 24 hours, while 
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resulting disability was assessed using the modified Rankin Scale (mRS, range 0-6 0 being no 
disability and 6 being death) at 90 days. These studies were approved by the local 
institutional review committees and each participant provided written informed consent. 
Imaging acquisition 
For both studies baseline computed tomography (CT) imaging included non-contrast 
CT (NCCT), CT perfusion (CTP) and CT angiography (CTA) using 64-slice scanners with 
120mm coverage. Non-contrast CT was followed by perfusion CT, comprising two 60-s 
series with 40 mL contrast agent (Ultravist 370; Bayer HealthCare, Berlin, Germany) injected 
at 6 mL s–1 followed by 30 ml of saline at 6 mL s–1. CT angiography was performed after 
perfusion CT with acquisition from the aortic arch to the top of the lateral ventricles6 with a 
second contrast injection of 40 mL contrast (Ultravist 370; Bayer HealthCare, Berlin, 
Germany) injected at 6 mL s–1 followed by 30 ml of saline at 6 mL s–1. Follow-up NCCT and 
CTA were performed with the same acquisition as the baseline scan in ATTEST and at 24-48 
hours after thrombolysis. Follow-up imaging for the Australia-TNK study were on 1.5T MRI 
scanners (Siemens Avanto). MRI sequences included an axial gradient-echo T2*-weighted 
series, diffusion-weighted imaging (DWI), magnetic resonance angiography (MRA), 
perfusion weighted imaging (PWI) and flow-attenuated inversion recovery (FLAIR).   
Pooled imaging analysis 
CT perfusion is able to identify both critically ischemic tissue and established 
infarction using thresholds of ischemia. The optimal measures have been validated against 
magnetic resonance imaging. The delay in the time it takes for blood to reach a particular 
region is used to identify ischemia (delay time), and the severity in the reduction of blood 
flow is used to identify infarction (cerebral blood flow). Individual patient imaging was 
centrally analysed with commercial software (MIStar, Melbourne, Australia), blind to clinical 
status and treatment allocation. Image analysis was performed in Newcastle, Australia by two 
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stroke neurologists and a clinical scientist. All perfusion imaging was processed using the 
singular value deconvolution (SVD) algorithm with delay and dispersion correction7 to 
generate maps of cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit 
time (MTT) and delay time (DT). Next, validated thresholds to measure the baseline 
penumbra and ischemic core volume applied. The perfusion lesion was defined as tissue with 
a delay time (DT) of >3 seconds and the ischemic core as tissue within the perfusion lesion 
(DT>3sec) but with a cerebral blood flow of <30% of baseline flow as determined from SVD 
output8. The penumbra was defined as tissue within the perfusion lesion but not in the 
ischemic core (DT>3sec, CBF >30%).9,10 The mismatch ratio was determined as the ratio of 
the perfusion lesion volume (DT>3sec) to the volume of the ischemic core (DT>3sec, 
CBF<30%). Severe hypoperfusion was defined as DT>8 seconds. 
We then classified patients as having target mismatch or no target mismatch based on 
whether they met the DEFUSE 2 target mismatch criteria (absolute mismatch volume 
>15mL, mismatch ratio >1.8, an baseline ischemic core <70mL, and volume of severely 
hypoperfused tissue <100mL). We used DT>8 seconds to define severely hypoperfused 
tissue. Penumbral salvage was defined as the proportion of baseline penumbra that did not 
progress to infarction on 24-48 hour NCCT (ATTEST) or 24 hour DWI (Australian study). 
Infarct growth was defined as the growth from baseline CTP ischemic core (DT>3sec, 
CBF<30%) volume to 24-48 hour NCCT or 24 hour DWI.  
All baseline CTA were assessed centrally for occlusion status and site of occlusion. 
The studies originally used slightly differing methods to define baseline vessel occlusion and 
vessel recanalization at 24-48 hours. For the pooled analysis we classified baseline occlusion 
status as either (i) normal, (ii) partial (using dynamic CTP source images to confirm/exclude 
residual antegrade flow by assessing if distal arteries branches filled with contrast prior to the 
8 
 
divisions), or (iii) complete occlusion (no antegrade flow).11 Patients with normal baseline 
CTA were not included in the recanalisation assessments.  
Brain haemorrhage outcomes were the occurrence of any parenchymal hematoma 
(PH), and large PH (PH2), as defined by the Second European-Australasian Acute Stroke 
Study (ECASS-2). We defined sICH according to the Safe Implementation of Thrombolysis 
in Stroke Monitoring Study12 as PH2 accompanied by neurological deterioration by ≥4 points 
on the NIHSS.  
Statistical analysis 
Statistical analysis was performed using Stata version 14. Firstly, in a post hoc 
analysis we compared between trials the baseline clinical and reprocessed imaging of 
Australia-TNK and ATTEST using Wilcoxon rank-sum test and Fisher exact tests where 
appropriate. We then pooled the per protocol patient information from the two studies for 
tenecteplase 0.25mg/kg and alteplase 0.9mg/kg doses to compare the between groups 
treatment effect of tenecteplase compared with alteplase on the clinical scores of the NIHSS 
and mRS as well as reprocessed imaging outcomes using Wilcoxon rank-sum test and Fisher 
exact tests. Where proportions were concerned, we fitted a logistic regression model to 
calculate the odds ratio (mRS 0-1 and ordinal mRS) and fitted a separate logistic regression 
model with target mismatch as an interaction term. The primary focus of the analysis was to 
determine patient treatment responsiveness on the mRS to tenecteplase compared with 
alteplase in the pooled analysis or in the target mismatch subgroups. Imaging outcomes were 
rates of brain haemorrhage (any PH, PH2, and sICH), penumbral salvage, infarct growth, and 
recanalisation.   
Next, patients were classified according to the target mismatch criteria and the 
treatment effect of tenecteplase vs alteplase was compared for target mismatch and non-target 
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mismatch patients separately as a subgroup analysis. We sought to compare the treatment 
effect of tenecteplase compared with alteplase in patients with target mismatch on the clinical 
scores of the NIHSS and mRS as well as reprocessed imaging outcomes using Wilcoxon 
rank-sum test and Fisher exact tests, or where proportions were concerned we fitted a logistic 
regression model to calculate the odds ratio to calculate the odds ratio (dichotomous mRS 0-1 
and ordinal mRS). For dichotomous outcomes the odds ratio represents the increase in 
likelihood of having a good outcome, while for and ordinal outcome the odds ratio represents 
the likelihood of not having a worse outcome with tenecteplase.   
  Lastly, we examined the number and percentage of patients with an mRS 0-1 outcome 
by treatment group and stratified those who met the target mismatch criteria and those who 
did not. To test whether the odds ratios of excellent outcome for target mismatch vs non-
target mismatch were statistically significantly different from each group we fitted a logistic 
regression model to determine if there was a statistically significant interaction for treatment 
on the target mismatch criteria. 
Results  
The 96 patients from the ATTEST per protocol analysis and 50 from the Australian-
TNK study were pooled for a combined analysis on 146 patients who were randomised to 
either 0.25 mg/kg tenecteplase or 0.9 mg/kg alteplase. Seventy-one patients received alteplase 
and 74 received tenecteplase. The Australian study had a higher baseline median baseline 
NIHSS scores (15 Australian-TNK vs 12 ATTEST, p=0.008) and earlier onset to treatment 
time (168min Australian-TNK vs 199min ATTEST, p=0.002, table 1). There were 
considerable differences in baseline imaging characteristics (table 1), with the Australian 
study having larger baseline perfusion lesions, greater mismatch and larger proportion of 
patients with any baseline vessel occlusion.  
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Pooled outcome analysis (all patients): tenecteplase vs alteplase.  
With respect to clinical outcomes, patients treated with tenecteplase had greater early 
clinical improvement (median NIHSS change, tenecteplase 7, alteplase 2, p=0.018, table 2), 
but did not have better 3 month outcomes (mRS 0-1 OR 1.77, 95% CI 0.89-3.51, p=0.102, 
ordinal OR 0.56, 95% CI, 0.31-1.01 p=0.055, table 3). In a logistic regression model using 
target mismatch status as an interaction term, there was also no significant improvement in 3 
month outcome in patients treated with tenecteplase (mRS 0-1 OR 1.77, 95% CI 0.89-3.51, 
p=0.076, interaction p=0.385). The tenecteplase treated patients showed more favourable 
imaging outcomes, with less infarct growth (tenecteplase 1.2mL, alteplase 18.3mL, p<0,001) 
and greater vessel recanalization (tenecteplase 87%, alteplase 37%, p<0.001, table 3). PH 
also tended to be lower with tenecteplase (3% tenecteplase vs 14% alteplase, p=0.02), but the 
rates of sICH were not significantly different (1 tenecteplase vs 5 alteplase, p=0.12, table 4).  
Pooled analysis (mismatch patients): tenecteplase vs alteplase. 
Seventy four of the 146 patients fulfilled target mismatch criteria, with 33 receiving 
tenecteplase and 35 alteplase, with a larger proportion of the Australian-TNK study patients 
(82%) fulfilling target mismatch criteria compared with ATTEST (34%, p<0.001).  Target 
mismatch patients treated with tenecteplase had greater early improvement (median NIHSS 
change, tenecteplase 6, alteplase 1, p<0.001), and less PH (tenecteplase 0% vs alteplase 21%, 
p=0.003) and sICH (tenecteplase 0%, alteplase 12%, p=0.04). Patients with target mismatch 
had significantly higher odds of achieving mRS 0-1 (mRS 0-1, OR 2.33, 95% CI 1.13-5.94, 
p=0.032, table 2) and were less likely to have a poor outcome (ordinal OR 0.31 CI 0.12-0.74, 
p=0.009). Target mismatch patients treated with tenecteplase also had higher recanalization 
rates (90% tenecteplase vs 33% alteplase, p<0.001) and less infarct growth (1.2mL 
tenecteplase vs 18.3mL alteplase, p<0.001, table 4 and supplementary table 1).  
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Pooled analysis: interaction between treatment and presence of mismatch on 90 day 
outcome 
Patients not fulfilling target mismatch criteria did not benefit from tenecteplase 
treatment (mRS 0-1, OR, 1.26, 95% CI, 0.45-3.51, p=0.65). Patients fulfilling target 
mismatch criteria were significantly more likely to have an excellent outcome when treated 
with tenecteplase compared with those who did not fulfil target mismatch criteria (mRS 0-1 
OR 2.33, vs 1.26, p=0.044). 
Discussion. 
 In a post hoc analysis of two randomised trials, we have identified that treatment with 
tenecteplase is associated with less PH events, greater early clinical improvement, reduced 
infarct growth and higher vessel recanalization rates. However, in the overall trial population 
there was no improvement in 90 day clinical outcome. Importantly however, in the subgroup 
of patients with target mismatch, there was a significantly better 90 day outcome from 
tenecteplase treatment compared with alteplase. The results of this pooled analysis provide 
additional evidence that tenecteplase is potentially a more effective and safer thrombolytic 
agent than alteplase. The entire pooled group had higher recanalisation rates with 
tenecteplase, approaching rates seen with the recent endovascular trials13,14,15,16 which carried 
over into improved early and 90 day clinical outcomes in the patients with target mismatch. 
The greater early clinical improvement seen in the entire pooled group was likely driven by 
the target mismatch patients as there were no differences in clinical outcomes seen between 
tenecteplase and alteplase in the sub-group without target mismatch.17   
There were significant baseline clinical and multimodal CT imaging characteristics 
differences between the two pooled trials, reflecting crucial differences in trial imaging 
eligibility criteria. The Australian-TNK study included a relatively homogenous patient group 
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based on multimodal CT imaging selection. Consequently the greater reperfusion and 
recanalisation seen with tenecteplase resulting in improved early and 90 day functional 
outcomes in patients with target mismatch were exaggerated and translated into better 
imaging and clinical outcomes than seen in ATTEST. A key limitation, however, of the 
enriched population selection approach is generalisability, with ATTEST addressing this 
issue by including a broader stroke population. This is most apparent as the ATTEST trial 
screened 157 thrombolysis eligible patients while the Australian TNK study screened 604 
thrombolysis eligible patients with 341 excluded due to imaging results such as no target 
mismatch or the presence of a large established infarct core. However, the current analysis 
demonstrates that the broad strategy used in ATTEST that does not require imaging criteria 
can lead to the inclusion of patients with little to gain from intravenous tenecteplase, as seen 
in the patients not fulfilling target mismatch criteria analysis where there was no clinical 
benefit from treatment with tenecteplase over alteplase in our limited sample. To that end, 
when target mismatch was added as an interaction term to the whole pooled population 
analysis, there was no change in outcomes which likely because our sample was 
underpowered to show such an interaction. In a heterogeneous condition such as stroke, 
broad inclusion may incur a large cost to trial power and risk overwhelming a potential major 
treatment effect in a particular sub-group that have the relevant biological target (e.g. target 
mismatch patients) 18,19 and as such require large pooled analyses such as this to demonstrate 
any clinical benefit.  
The higher brain haemorrhage rates in the alteplase treated patients is of particular 
interest given it appears to be driven by haemorrhage occurring mainly in the target mismatch 
patients. The mechanism is not well understood20, but prior alteplase studies indicates late 
recanalization is associated with higher rates of haemorrhage.21 This may make tenecteplase 
treatment a preferential treatment option for patients at high risk of haemorrhage, such as the 
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elderly or those recently having undergone surgery. In the current study, we saw greater 
infarct growth in the target mismatch alteplase group than with tenecteplase, possibly 
reflecting less effective (and later) recanalization and reperfusion with alteplase. Thus, in the 
alteplase target mismatch patients the increased bleeding may have occurred as a result of late 
reperfusion into tissue which was originally penumbral but had progressed to infarction by 
the time of reperfusion. The rates of brain haemorrhage were much lower in the non- target 
mismatch patients, likely reflecting smaller ischaemic lesions in this group. Additionally, 
alteplase is known to interact significantly with the blood brain barrier (BBB) which is 
thought to further exacerbate the risk of bleeding, while tenecteplase has much less BBB 
interaction and may lead to reduced risk of HT and PH22. 
Limitations of this study include a relatively small dataset from two clinical phase 2 
trials which were not designed to test clinical benefit, and with significant heterogeneity in 
design and imaging outcome measurement. Thus these results are hypothesis generating. In 
addition, the rates of transient ischemic attack, stroke reoccurrence and cardio vascular 
accident and death beyond 90 days cannot be assessed in the current study due to the limited 
reporting time frame. A prospective randomised clinical trial of patients meeting target 
mismatch criteria is required to confirm the study’s findings  
The potential for higher rates of early recanalisation, with lower PH risk and 
improved early as well as 90 day outcomes compared with alteplase strongly supports large 
phase III trials of tenecteplase for stroke thrombolysis. Improvements in thrombolytic drug 
safety and efficacy remain critically important even in the setting of the recent positive 
endovascular treatment trials, since such treatment was adjunctive to thrombolytic therapy 
and endovascular treatment is likely to remain an option for a minority of patients. 
Complementary phase III trial designs for ongoing studies will yield important information 
on a potentially safer and more effective intravenous thrombolytic agent, tenecteplase, as well 
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as more evidence to support the generalisability of multimodal CT selection of patients for 
reperfusion therapy. 
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Comparison between trials 
Clinical Characteristics  
  Australia-TNK n=50 ATTEST n=96 p value 
Median age (years, 
IQR) 
 
69 (14) 73 (18) 0.43 
Median symptom onset 
to imaging (mins, IQR) 
123 (62) 181 (63) 0.011 
Median symptom onset 
to Treatment time 
(mins, IQR) 
168 (55) 198 (64) 0.002 
Median baseline 
NIHSS (IQR) 
15 (4) 11 (9) 0.008 
 
Median 24 hour NIHSS 
(IQR) 
4 (13) 7 (12) 0.129 
Median mRS (IQR) 1 (3) 3 (3)  
Hypertension (%) 32% 16% 0.052 
Diabetes Mellitus (%) 
 
14% 33% 0.014 
Hyperlipidaemia (%) 
 
48% 16% <0.001 
Atrial Fibrillation at 
admission 
38% 27% 0.255 
Anti-platelets  54% 58% 0.813 
Imaging Characteristics  
 Australia-TNK n=50 ATTEST n=96 p value 
Median baseline 
ischaemic core volume 
(mL, IQR) 
13 (14) 9 (31) 0.33 
Median baseline 
perfusion lesion volume 
(mL, IQR) 
34 (48) 23 (61) <0.001 
Median baseline 
mismatch ratio (IQR) 
2.43 (2.65) 1.77 (1.91) <0.001 
Complete vessel 
occlusion 
41/50 (82%) 28/96 (29%) <0.001 
Occlusion site 
ICA 
M1 
M2 
M3 
ACA/PCA 
 
0/50 (0%) 
37/50 (74%) 
8/50 (16%) 
0/50 (0%) 
3/50 (6%) 
 
13/96 (14%)  
29/96 (30%) 
20/96 (21%) 
5/96 (5%) 
2/96 (2%) 
 
0.009 
0.004 
0.664 
0.171 
0.609 
Median infarct growth 
(mL, IQR) 
21 (25) 4 (18) 0.551 
Median penumbral 
salvage (mL, IQR) 
51 (46) 14 (32) 0.013 
Complete 
recanalization 
58% (29 patients) 65% (62 patients) 0.647 
18 
 
                                                                                                                                                        
Table 1. A comparison of clinical and imaging data between the ATTEST and Australian-
TNK trials. Occlusion site reports the source location of hypo-perfusion and does not 
represent occlusion severity. IQR- Interquartile range. NIHSS – National Institutes of Health 
Stroke Scale. mRS –Modified Rankin score. ICA – Internal carotid artery. M1 – Middle 
cerebral artery. ACA – Anterior cerebral artery. PCA- posterior cerebral artery. 
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Comparison between treatment groups 
Baseline clinical Characteristics 
  tenecteplase n=75 alteplase n=71 p value 
Median age (years, 
IQR) 
72 (17) 73 (19) 0.225 
Median symptom onset 
to imaging (mins, IQR) 
170 (73) 169 (81) 0.621 
Median symptom onset 
to Treatment time 
(mins, IQR) 
180 (61) 186 (68) 0.445 
Median acute NIHSS 
(IQR) 
13 (7) 12 (7)  
Hypertension (%) 32% 30% 0.884 
Diabetes Mellitus (%) 
 
30% 23% 0.441 
Hyperlipidaemia (%) 
 
30% 23% 0.441 
Atrial Fibrillation at 
admission 
36% 24% 0.187 
Anti-platelets  58% 55% 0.906 
Imaging Characteristics  
 tenecteplase n=75 alteplase n=71 p value 
Median baseline 
ischaemic core volume 
(mL, IQR) 
10 (19) 12 (27) 0.409 
Median baseline 
perfusion lesion volume 
(mL, IQR) 
26 (58) 28 (64) 0.578 
Median baseline 
mismatch ratio (IQR) 
1.98 (2.18) 2.05 (2.35) 0.509 
Complete vessel 
occlusion 
33 (42%) 36 (48%) 0.770 
Occlusion site 
None 
ICA 
M1 
M2 
M3 
ACA/PCA 
 
12/75 (16%)  
1/75 (1%) 
43/75 (58%) 
14/75 (19%) 
  1/75 (1%) 
 4 /75 (5%) 
 
 20/71(28%) 
  5/71 (7%) 
27/71 (39%) 
14/71 (19%) 
  4/71 (6%) 
  1/71 (1%) 
 
0.177 
0.209 
0.189 
1.00 
0.366 
0.368 
Table 2. A comparison of baseline clinical and imaging data between the teneteplase and 
alteplase treated patients in the pooled analysis. Occlusion site reports the source location of 
hypo-perfusion and does not represent occlusion severity. IQR- Interquartile range. NIHSS – 
National Institutes of Health Stroke Scale. mRS –Modified Rankin score. ICA – Internal 
carotid artery. M1 – Middle cerebral artery. ACA – Anterior cerebral artery. PCA- posterior 
cerebral artery. 
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Comparison of clinical outcomes between treatment groups of tenecteplase vs 
alteplase in entire pooled population 
 tenecteplase 
n=75 
alteplase n=71 Odds ratio (95th CI), 
and/or p value 
Early clinical 
improvement 
(median reduction in 
baseline -24 hour 
NIHSS in matched 
NIHSS patients, , 
IQR in brackets) 
7 (5) 2 (4) p=0.018 
Excellent 90 day 
outcome (mRS 0-1) 
 
33 (44%) 
 
 
22 (31%) 
 
 
1.77, (0.89-3.51) p=0.102 
 
Poor 90 day outcome 
(mRS 5-6) 
11 (15%) 
 
16 (23%) 
 
0.59 (0.25, 1.38) p=0.227 
 
Comparison between treatment groups of tenecteplase vs alteplase 
in patients meeting the target mismatch criteria on baseline perfusion imaging 
 tenecteplase 
n=33 
alteplase n=35 Odds ratio (95th CI), 
and/or p value 
Early clinical 
improvement 
(median reduction in 
baseline -24 hour 
NIHSS in matched 
NIHSS patients, , 
IQR in brackets) 
6 (8) 1 (6) p<0.001 
Excellent 90 day 
outcome (mRS 0-1) 
 
17 (53%) 
 
 
8 (24%) 
 
 
2.33 (1.13, 5.94) p=0.032 
 
Poor 90 day outcome 
(mRS 5-6) 
5 (13%) 
 
11 (32%) 
 
0.30 (0.09, 0.97) p=0.048 
 
Table 3. Comparison of clinical outcomes between tenecteplase and alteplase patients in all 
patients and only those meeting the target mismatch criteria from ATTEST and Australian- 
tenecteplase studies. A low ordinal mRS is used to indicate that tenecteplase treated patients 
were less likely to have a high mRS score at 90 days compare to alteplase treated patients. 
IQR- Interquartile range. NIHSS – National Institutes of Health Stroke Scale. mRS –
Modified Rankin score. ICA – Internal carotid artery. M1 – Middle cerebral artery. ACA – 
Anterior cerebral artery. PCA- posterior cerebral artery. 
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Comparison of imaging outcomes between treatment groups in entire pooled 
population  
 tenecteplase 
n= 75 
alteplase 
n=71 
Comparison 
Any PH 
 
2 (3%) 10 (14%) Odds ratio 0.16 (95% CI 
0.03, 0.78) p=0.02 
sICH 
 
1 (1%) 5 (7%) Odds ratio 0.18 (95% CI 
0.02, 1.54), p=0.12 
Median infarct growth 
(IQR) 
 
8 (40) 10 (41) p=0.006 
Median penumbral salvage 
(IQR) 
 
28 (50) 23 (48) 0.279 
Complete recanalization 
 
 
54/62 
(87%) 
19/52  
(37%) 
Odds ratio 11.72 (95% 
CI 4.61, 21.79) p<0.001 
 
Comparison of imaging outcomes in patients meeting the target mismatch criteria on 
baseline perfusion imaging  
 tenecteplase 
n= 33 
alteplase 
n=35 
Comparison 
Any PH 
 
0 (0%) 7 (21%) p=0.015 
sICH 
 
0 (0%) 4 (12%) p=0.119 
Median infarct growth, mL 
(IQR) 
 
 18 (34) 26 (44) <0.001 
Median penumbral salvage 
(IQR) 
 
40 (45) 25 (50) <0.001 
Complete recanalization 
 
 
29/33 
(87%) 
12/35 
(34%) 
Odds ratio 17.5 (95% CI 
4.85, 63.14) p<0.001 
Table 4. Comparison of imaging outcomes between tenecteplase and alteplase 
patients in all patients and only those meeting the target mismatch criteria from ATTEST and 
Australian-TNK studies. IQR- Interquartile range. NIHSS – National Institutes of Health 
Stroke Scale. mRS –Modified Rankin score. ICA – Internal carotid artery. M1 – Middle 
cerebral artery. ACA – Anterior cerebral artery. PCA- posterior cerebral artery. 
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Figure 1. Comparison patient outcomes between tenecteplase and alteplase patients in all 
patients from ATTEST and Australian-TNK studies. In a pooled analysis, patients did not 
have better 3 month outcomes on dichotomous outcome measures (mRS 0-1 1.75 CI, 0.89, 
3.75 p=0.11) or ordinal analysis (OR 0.56 CI, 0.31-1.01, p=0.055) 
 
 
 
Figure 2. Comparison of patient outcomes in those fulfilling target mismatch criteria. 
Tenecteplase treated patients with mismatch had higher chance of achieving mRS 0-1 at 90 
days (OR 4.97, 95% CI, 1.76-14.07, p=0.002), which also carried over into a reduced risk of 
poor outcomes in the ordinal mRS outcome analysis (OR 0.3, 95% CI, 0.12-0.74 p=0.009). 
 
 
